Vanguard Group Inc Summit Therapeutics Inc. Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 7,269,243 shares of SMMT stock, worth $56.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,269,243

Previous 7,014,982 3.62%

Holding current value

$56.7 Million

Previous $18.3 Million 64.37%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$2.55 - $5.07 $648,365 - $1.29 Million	254,261 Added 3.62%	7,269,243 $30.1 Million
Q4 2023 Feb 14, 2024	BUY	$1.67 - $2.83 $1.54 Million - $2.6 Million	919,307 Added 15.08%	7,014,982 $18.3 Million
Q3 2023 Nov 14, 2023	SELL	$1.54 - $2.42 $7,415 - $11,652	-4,815 Reduced 0.08%	6,095,675 $11.4 Million
Q2 2023 Aug 14, 2023	BUY	$1.32 - $2.81 $6.12 Million - $13 Million	4,635,361 Added 316.38%	6,100,490 $15.3 Million
Q1 2023 May 15, 2023	BUY	$1.38 - $5.41 $29,767 - $116,699	21,571 Added 1.49%	1,465,129 $2.56 Million

Q4 2022 Feb 10, 2023	BUY	$0.68 - $5.31 $453,992 - $3.55 Million	667,636 Added 86.04%	1,443,558 $6.14 Million
Q2 2022 Aug 12, 2022	SELL	$0.92 - $2.38 $124,636 - $322,428	-135,474 Reduced 14.86%	775,922 $776,000
Q1 2022 May 13, 2022	BUY	$2.0 - $3.45 $9,018 - $15,556	4,509 Added 0.5%	911,396 $2.23 Million
Q4 2021 Feb 14, 2022	BUY	$2.45 - $5.64 $3,324 - $7,653	1,357 Added 0.15%	906,887 $2.44 Million
Q3 2021 Nov 12, 2021	BUY	$4.83 - $8.27 $123,802 - $211,976	25,632 Added 2.91%	905,530 $4.54 Million
Q2 2021 Aug 13, 2021	BUY	$5.15 - $8.46 $4.53 Million - $7.44 Million	879,898 New	879,898 $6.56 Million

Others Institutions Holding SMMT

# of Institutions

107

Shares Held

41.3M

Call Options Held

103K

Put Options Held

29.9K

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $1.57B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Summit Therapeutics Inc. Transaction History